Please login to the form below
Vyndaqel
This page shows the latest Vyndaqel news and features for those working in and with pharma, biotech and healthcare.
Pfizer lifts 2021 guidance as sales of its BioNTech-partnered vaccine continue to climb
Other notable gains in the quarter included rare disease medication Vyndaqel/Vyndamax, which was up by 77%, while sales of its anticoagulant therapy Eliquis were also up by 13% driven by
Latest news
-
Pfizer’s COVID-19 vaccine yields $3.5bn in first quarter sales
the rare heart disease treatment Vyndaqel.
-
Pfizer CEO says COVID-19 vaccine efficacy data could come ‘soon’
This increase was helped by a 125% increase in global revenues for its rare disease med Vyndaqel (tafamidis), totalling $351m.
-
Pfizer’s Vyndaqel is first EU therapy for ATTR cardiomyopathy
EU approval will help drug achieve blockbuster status. Pfizer’s resurgent rare disease drug Vyndaqel has had its uses extended by the EMA, becoming the first drug in the EU for ... Prior to Vyndaqel, treatment options for patients with ATTR
-
Vyndaqel a bright spot as Pfizer comes under pressure
The big boost for Pfizer came from Vyndaqel/Vyndamax (tafamidis) for rare disease transthyretin-mediated amyloidosis (ATTR), which swelled to $213m in the fourth quarter from just $39m a year earlier ... As of the end of 2019 more than 9, 000 ATTR
-
Alnylam gains key NICE approval for Onpattro
decision. The two rivals also face competition from Pfizer’s Vyndaqel (tafadamis). It has been available in Europe for a number of years as a polyneuropathy treatment, but recently gained US ... The company also highlighted the fact that around a third
Pfizer’s COVID-19 vaccine yields $3.5bn in first quarter sales
Pfizer CEO says COVID-19 vaccine efficacy data could come ‘soon’
Vyndaqel a bright spot as Pfizer comes under pressure
Alnylam gains key NICE approval for Onpattro
More from news
Approximately 1 fully matching, plus 11 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
to 2025 built on the Prevnar franchise, rare disease therapy Vyndaqel (tafamidis), breast cancer therapy Ibrance (palbociclib) and arthritis drug Xeljanz (tofacitinib), among others. ... Standing in its way is a similarly priced antisense rival from
-
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
produced impressive data for its Vyndaqel (tafamidis). ... Vyndaqel has been available in Europe since 2011 for Transthyretin (TTR) amyloid polyneuropathy, but isn’t yet approved in the US.
-
Tough times for pharma in Portugal
spondylitis. For instance, the Portuguese Association of Amyloidosis (APP) is petitioning parliament for access to Pfyzer's Vyndaqel (tafamidis).
20 for 2020 – Five pharma leaders to watch in 2020
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Tough times for pharma in Portugal
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Events Executive
-
Depending on Experience
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
-
Digital account director
-
Competitive
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Understanding the ‘real world’ starts and ends with the patient
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- Sanofi raises profit forecast following positive Q2 results
- Biogen/Eisai push for second approval in Alzheimer’s disease
- Reducing primary care antibiotic use may not be enough to counter antimicrobial resistance
- SoftBank buys $5bn stake in Roche
- Live Webinar: Making Wearable Technology Scalable and Adoptable
- Live Webinar: Transforming the Future of Health & Aging from a Global Health & Social Impact Approach
- Investors respond positively to “strong” Eli Lilly results
- Amanda Pritchard becomes NHS England’s first female chief executive
- Biogen/Eisai push for second approval in Alzheimer’s disease
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Understanding the ‘real world’ starts and ends with the patient
- BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
- Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies
PMHub
Onyx Health Ltd
Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...
Latest intelligence
- Ask the writers: Transitioning from academia to medical writing
- Porterhouse Medical's talented writers talk about their transition from academia and give advice to those people considering a career in medical writing...
- Strategic launch planning: familiar framework, new mindset
- By James Aird...
- Guide
- How to embrace behavioural science principles in healthcare MR...
